secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115766
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance
--------------------------------------------------------------------------------

- Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.
- Adjusted EBITDA negative $3.1M (vs positive $4.7M a year ago); operating costs rose to $41.2M.
- Commercial cell/gene therapy revenue up 54% to $6.6M; supports record 670 clinical trials (81 Phase 3).
- Affirms FY2023 revenue guidance $233-243M; cash & investments $465.9M at quarter end.
- Repurchased $31.3M of convertible notes for $25.1M, recording $5.7M gain on debt extinguishment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/0001104659-23-115766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/tm2330255d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer